- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Merck to wind down Gardasil production at N.C. plant, lay off 150-plus | ||
| Fr | Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycle | ||
| Fr | Sanofi, Genentech, Kedrion back star-studded bleeding disorder awareness campaign | ||
| Fr | After CHMP nod, Moderna CEO applauds EU's 'rigorous scientific review' | ||
| Fr | UCB's fast-growing Bimzelx leaps across blockbuster sales threshold as HS momentum builds | ||
| Fr | As SCOTUS takes on 'skinny label' review, top US lawyer sides with generics maker | ||
| Fr | Fierce Pharma Asia-China deal growth; Daiichi's new CMO; Astellas-Vir bispecific tie-up | ||
| Fr | Autoimmune CAR-T:'¯Navigating the FDA's new regulatory playbook | ||
| Do | Boehringer's Hernexeos secures speedy first-line expansion in FDA's 2nd national priority nod | ||
| Do | After delay, CDC vaccine panel sets new dates to discuss long COVID and mRNA shot safety | ||
| Do | OMG-argenx scores again with Vyvgart in ocular myasthenia gravis | ||
| Do | Eisai points the way to kidney cancer support with Kompass digital hub | ||
| Do | Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies | ||
| Do | Protagonist plans to pocket $400M from Takeda rather than split US rusfertide profits | ||
| Do | Viatris to cut 10% of workforce in 3-year overhaul, discloses fire at India plant | ||
| Mi | As BridgeBio's Attruby launch accelerates, CEO shrugs off recent EU pricing pressure fears | ||
| Mi | Charles River sells manufacturing and discovery businesses to fulfill promised pivot | ||
| Mi | To reach consumers interested in GLP-1s, audio is 'dramatically underutilized': SiriusXM survey | ||
| Mi | Sanofi assists Boston's World Cup plans with play for local engagement | ||
| Mi | How Evinova is Integrating AI into Clinical Development to Bring Big Impact to Big Pharma | ||
| Mi | With Texas site, Novartis rounds out radiopharma production plans amid $23B US investment blitz | ||
| Di | Novo to knock down Ozempic, Wegovy list prices next year, but self-pay channels unaffected | ||
| Di | BioMarin pulls hemophilia gene therapy Roctavian, taking $240M hit after divestiture efforts flounder | ||
| Di | AstraZeneca CEO pay hits $23.9M amid 'significant geopolitical uncertainty' in 2025 | ||
| Di | Indivior picks Havas to lead US marketing efforts as DTC push ramps up |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.